排序方式: 共有3条查询结果,搜索用时 15 毫秒
1
1.
Masaki Inoue MD Yoshiaki Tanaka Nagatoshi Sugita Masato Yamasaki Tadashi Yamanaka Junnosuke Minagawa Karo Nakamuro Toshiro Tani Yoshio Okudaira Tuguhiro Karita Katsumi Takayama Tatsuo Ide Osamu Tanizawa 《Biotherapy》1993,6(1):13-18
The effect of immunotherapy using sizofiran (SPG) on the prognosis of patients with ovarian cancers was prospectively studied in a total of 68 patients, who were randomly assigned to either a cisplatin, adriamycin and cyclophosphamide (PAC) therapy group or a PAC plus SPG combination therapy group.The survival rate was significantly higher in patients with stage Ic, II or III cancers treated with the PAC plus SPG combination, compared with the patients treated with PAC alone. In the SPG-receiving patients with stage Ic or more advanced cancers who were treated with four cycles or more of PAC, the outcome was improved (Cox-Mantel, p=0.074; generalized Kruskal-Wallis, p=0.032). Similar improvement was also observed in the patients with non-serous adenocarcinomas (Cox-Mantel, p-0.076; generalized Krukal-Wallis, p=0.045). No side effects attributable to SPG were recorded.The present results suggest that the use of SPG in combination with long-term chemotherapy improves the postoperative prognosis in ovarian cancer patients.Abbreviations SPG
sizofiran 相似文献
2.
Tomoyuki Yoshida M.D. Tetsuro Saeki Yumiko Aoyama Tadao Okudaira Takuya Okada Sotaro Funasaka 《Biotherapy》1997,10(2):115-120
It has been reported that immunologic function is deteriorated in head and neck cancer patients by primary therapies such
as surgery, irradiation and chemotherapy or tumor itself. As previously described by us, immunologic dysfunction in such patients
may be recovered by treatment with BRMs.
In the present study, we investigated the effects of BRMs on survival of patients who had primarily been treated in our clinic.
Fifty-one patients (23 patients; Stage I or Stage II, 28 patients; Stage III or Stage IV) were treated with BRMs (BRM group),
and 49 patients (22 patients; Stage I or Stage II, 27 patients; Stage III or Stage IV) were employed as controls (Control
group). The results obtained were as follows: (1) In patients of all Stages, the survival period was significantly (p<0.05)
longer in BRM group than in Control group; (2) The survival periods of patients of Stage I or Stage II were not different
between the groups; and (3) The survival period of BRM group was significantly (p<0.05) longer than that of Control group
in patients of Stage III or Stage IV. There were observed more patients in BRM group who survived for a prolonged period.
These results suggest that BRMs may be useful for recovering immunologic function in head and neck cancer patients particularly
of Stage III or Stage IV who usually receive multimodality therapy. 相似文献
3.
Yoshinori Tsuchiya Michiko Matsutani Mamoru Inoue Soichiro Sato Taiji Asano Motoyuki Yajima 《Cancer immunology, immunotherapy : CII》1991,34(1):17-23
Summary The number of bone marrow cells in C3H/He mice was reduced 3–4 days after treatment with 130 mg/kg intraperitoneal 5-fluorouracil (5-FU). Higher rates of spontaneous proliferation and natural killer (NK) activity, accompanied by an increase in asialoGM1-positive cells, were observed in treated mice. When sizofiran at a dose of 200 µg/animal was intramuscularly injected after 5-FU treatment, the rates of proliferation and NK activity of bone marrow cells were higher than with 5-FU alone. The cell number was not influenced by sizofiran alone. These results indicate that all precursors of the various mature cell types (including NK cells) differentiate and regenerate rapidly to replace cells damaged by 5-FU treatment, and that sizofiran has the potential to assist this recovery. These results suggest that administration of sizofiran after chemotherapy may be useful in cancer patients. 相似文献
1